This may partially explain the failure of a clinical trial of nucleoside 3′-C-ethynylcytidine (TAS-106), a cytidine analogue subjected to UCK2 phosphorylation, in treatment of head and neck cancer and nasopharyngeal cancer36. Here, UCK2 is linked to head and neck cancer.